Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biphasic Insulin Aspart 30 Initiation in T2D Failing OADs
NCT00605111Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2003
- Primary completion
- Oct 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 11 weeks. Started Dec 2003; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00605111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605111.